Management of Alcohol Withdrawal

Rationale for Treatment Approach

The American Association for the Study of Liver Diseases recommends benzodiazepines as the "gold standard" and first-line treatment for alcohol withdrawal syndrome (AWS) due to their proven efficacy in reducing withdrawal symptoms and preventing serious complications such as seizures and delirium tremens 1, 3
Patients undergoing alcohol withdrawal are at higher risk of substance abuse, making benzodiazepines with abuse potential concerning, but still preferable to non-standard agents like zolpidem 1

The Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) is a validated tool used to assess withdrawal severity; scores >8 indicate moderate AWS while scores ≥15 indicate severe AWS 1
Symptom-triggered medication regimens are recommended rather than fixed-dose schedules to prevent drug accumulation 1

Long-acting benzodiazepines (diazepam, chlordiazepoxide) provide better protection against seizures and delirium 1, 3
Short and intermediate-acting benzodiazepines (lorazepam, oxazepam) are safer options for elderly patients or those with hepatic dysfunction 1, 3
Benzodiazepine treatment should be limited to the initial 10-14 days to minimize risk of dependence 1

For patients with decompensated liver disease, symptom-adapted dosing and short-acting benzodiazepines are recommended 3
Thiamine supplementation should be provided to all patients with AWS to prevent Wernicke's encephalopathy 4
Inpatient treatment is recommended for patients at risk of severe withdrawal, those with physical/psychiatric comorbidities, or inadequate support systems 5, 6

Zolpidem may cause paradoxical agitation, particularly in patients with underlying neurological conditions like those experiencing alcohol withdrawal 7
Using evidence-based treatments like benzodiazepines rather than non-indicated medications like zolpidem is essential for reducing morbidity and mortality 1, 5